Holen Sie sich die Stockscreener-App
8.30
0.36%
0.03
Handel nachbörslich:
8.35
0.05
+0.60%
Schlusskurs vom Vortag:
$8.27
Offen:
$8.3
24-Stunden-Volumen:
3.64M
Relative Volume:
0.79
Marktkapitalisierung:
$2.56B
Einnahmen:
$493.67M
Nettoeinkommen (Verlust:
$-104.69M
KGV:
-24.41
EPS:
-0.34
Netto-Cashflow:
$-31.51M
1W Leistung:
+1.22%
1M Leistung:
+4.53%
6M Leistung:
+27.50%
1J Leistung:
-17.41%
1-Tages-Spanne:
$8.16
$8.35
1-Wochen-Bereich:
$8.01
$8.505
52-Wochen-Spanne:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Firmenname
Amicus Therapeutics Inc
Sektor
Branche
Telefon
(609) 662-2000
Adresse
47 HULFISH STREET, PRINCETON, NJ
Vergleichen Sie FOLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
8.30 | 2.55B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Hochstufung | Needham | Hold → Buy |
| 2025-07-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Eingeleitet | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2024-05-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Fortgesetzt | Goldman | Neutral |
| 2022-01-14 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-27 | Eingeleitet | Needham | Hold |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2021-02-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-02-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-06-05 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Eingeleitet | Janney | Buy |
| 2019-01-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Eingeleitet | Citigroup | Neutral |
| 2018-08-17 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
| 2017-09-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-08-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-01-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Eingeleitet | BofA/Merrill | Buy |
| 2016-04-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2016-04-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2015-09-16 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten
What Fibonacci levels say about Amicus Therapeutics Inc. reboundPortfolio Return Report & Consistent Profit Trade Alerts - newser.com
Can volume confirm reversal in Amicus Therapeutics Inc.Market Growth Summary & Reliable Breakout Stock Forecasts - newser.com
Will a bounce in Amicus Therapeutics Inc. offer an exitMarket Movers & Risk Controlled Stock Alerts - newser.com
Heatmap analysis for Amicus Therapeutics Inc. and competitorsEarnings Recap Summary & Entry Point Confirmation Signals - newser.com
What macro factors could drive Amicus Therapeutics Inc. (AM6) stock higherJuly 2025 Summary & Accurate Technical Buy Alerts - newser.com
Developing predictive dashboards with Amicus Therapeutics Inc. dataJuly 2025 Rallies & Fast Exit and Entry Strategy Plans - newser.com
Amicus Therapeutics Inc. stock prediction for this weekMarket Sentiment Report & High Accuracy Swing Trade Signals - newser.com
Is Amicus Therapeutics Inc. (AM6) stock trading at attractive multiplesPortfolio Gains Report & Risk Controlled Stock Pick Alerts - newser.com
Real time scanner hits for Amicus Therapeutics Inc. explainedJuly 2025 Selloffs & Verified Entry Point Detection - newser.com
Amicus Therapeutics (NASDAQ:FOLD) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease - Nasdaq
Amicus Therapeutics (NASDAQ:FOLD) Upgraded to "Strong-Buy" at Zacks Research - MarketBeat
Q3 EPS Forecast for Amicus Therapeutics Lifted by Analyst - MarketBeat
What Does Wall Street Think About Amicus Therapeutics (FOLD)? - MSN
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy - sharewise.com
Is Amicus Therapeutics Inc AM6 a good long term investmentVWAP Trading Strategies & Consistent Triple Returns - earlytimes.in
How the Narrative Around Amicus Therapeutics Is Shifting Amid Legal and Pipeline Developments - Yahoo Finance
Zacks.com featured highlights include Amicus Therapeutics, Micron Technology and General Dynamics - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Pompe Disease Market Research 2025: Treatment, Route of Administration, and Region Analysis and Fore - PharmiWeb.com
Pompe Disease Market Research 2025: Treatment, Route of Administration, and Region Analysis and Forecast to 2035 Featuring Amicus Therapeutics, Astellas, BioMarin, Maze Therapeutics, Oxyrane ParasailResearchAndMarkets.com - The AI Journal
Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns - TradingView
What RSI levels show for Amicus Therapeutics Inc. (AM6) stockStop Loss & Weekly High Potential Stock Alerts - newser.com
A Look at Amicus Therapeutics’s Valuation After Analyst Upgrade and Improved Outlook (FOLD) - Yahoo Finance
Is Amicus Therapeutics Inc. (AM6) stock a top pick for value investorsWeekly Volume Report & Fast Gain Swing Alerts - newser.com
Market reaction to Amicus Therapeutics Inc.’s recent newsEarnings Overview Summary & Real-Time Chart Pattern Alerts - newser.com
How to forecast Amicus Therapeutics Inc. trends using time seriesJuly 2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Needham Upgrades Amicus Therapeutics(FOLD.US) to Buy Rating, Announces Target Price $14 - 富途牛牛
Technical signs of recovery in Amicus Therapeutics Inc.2025 Investor Takeaways & AI Driven Price Forecasts - newser.com
Using Ichimoku Cloud for Amicus Therapeutics Inc. technicalsWeekly Profit Recap & Reliable Volume Spike Alerts - newser.com
Can Galafold Drive Amicus' Growth Through the Rest of 2025? - sharewise.com
Amicus Therapeutics (NASDAQ:FOLD) Trading Up 6.5%What's Next? - MarketBeat
Top chart patterns to watch in Amicus Therapeutics Inc.2025 Big Picture & Free High Return Stock Watch Alerts - newser.com
Pompe Disease Market Analysis Report 2025-2035: Enzyme Replacement Therapies and Approvals of Myozyme and Nexviazyme Drive Steady Growth - GlobeNewswire Inc.
Can Amicus Therapeutics Inc. rally from current levelsBond Market & Long Hold Capital Preservation Tips - newser.com
Finanzdaten der Amicus Therapeutics Inc-Aktie (FOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amicus Therapeutics Inc-Aktie (FOLD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Campbell Bradley L | President and CEO |
Feb 19 '25 |
Sale |
10.00 |
400 |
4,000 |
1,150,657 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):